<DOC>
	<DOCNO>NCT01694160</DOCNO>
	<brief_summary>The main objective study examine paricalcitol may reduce progression graft fibrosis proteinuria kidney transplant patient . Cyclosporine tacrolimus detrimental long-term effect induce graft fibrosis . About 50 % graft loss relate interstitial fibrosis . Paricalcitol vitamin D receptor activator indicate treatment secondary hyperparathyroidism . Paricalcitol known exert anti-inflammatory antifibrotic attenuate cyclosporine-induced fibrosis . Paricalcitol also show renoprotective reduce proteinuria . No randomized control trial paricalcitol perform renal transplant patient examine effect proteinuria graft fibrosis .</brief_summary>
	<brief_title>Oral Paricalcitol Renal Transplant Recipients Reducing Albuminuria</brief_title>
	<detailed_description>77 randomize , 37 paricalcitol , 40 treatment</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>kidney transplant patient Previously transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>kidney transplant patient</keyword>
	<keyword>Albuminuria</keyword>
</DOC>